Read more
Errata slip copyright 2018 inserted at end.
List of contents
SECTION I. PHARMACOLOGICAL AND CLINICAL APPLICATIONS1. Overview of Brain Tumor Epidemiology and Histopathology2. Clinical Pharmacology of Brain Tumor Chemotherapy3. Antiepileptic drugs and chemotherapy: Potential interactions and impact on treatment of patients with cancer4. Brain Tumor Models for Cancer Therapy5. Genomics and proteomics in neuro-oncology6. Chemotherapy Resistance7. Clinical Trial Design and Implementation in Neuro-Oncology8. Biology of the Blood-Brain and Blood-Brain Tumor Barriers
SECTION II. INNOVATIVE CHEMOTHERAPY DELIVERY9. Intra-arterial Chemotherapy10. Blood-Brain Barrier Disruption Chemotherapy11. Interstitial Chemotherapy and Polymer-Drug Delivery12. Intratumoral Chemotherapy and Convection-Enhanced Delivery13. Marrow-Ablative Chemotherapy with Autologous Hematopoietic Progenitor Cell Rescue in Brain Tumors14. CSF Dissemination of Primary Brain Tumors 15. Gene/Viral Treatment Approaches for Malignant Brain Cancer16. Nanoparticles as Therapeutic Agents for Brain Tumors
SECTION III. MOLECULAR BIOLOGY AND MOLECULAR THERAPEUTICS17. Overview of Molecular Genetics of Brain Tumors18. Cell Cycle Regulation19. Targeting cell cycle proteins in brain cancer20. Apoptosis Pathways and Chemotherapy in Brain Tumors21. Growth Factor Signaling Pathways and Targeted Therapy22. Targeting the RAS-RAF-MEK-ERK Signaling Pathway in Gliomas23. PI3-kinase, Akt, mTOR and Treatment24. Scatter Factor/HGF and C-MET in Glioblastoma25. Targeting the sonic hedgehog pathway in brain cancers: Advances, limitations, and future directions26. Angiogenesis and angiogenesis inhibitors in brain tumors27. Bevacizumab and Brain Tumors28. Histone Deacetylase Inhibitors as Therapeutic Agents
SECTION IV. CHEMOTHERAPY FOR SPECIFIC TUMORS - ADULTS 29. Historial and conventional chemotherapy approaches for high grade astrocytomas 30. The use of temozolomide for chemo-radiation and adjuvant therapy of high-grade gliomas31. Molecular Treatment of High-Grade Glioma32. Chemotherapy of Low-Grade Astrocytomas33. Chemotherapy of Oligodendrogliomas34. Chemotherapy of Primary Central Nervous System Lymphoma35. Chemotherapy for Medulloblastoma in Adults36. Chemotherapy of Adult Ependymoma 37. Chemotherapy for Glioneuronal Tumors38. Medical therapy of Schwannomas 39. Chemotherapy of Pineal Parenchymal Tumors40. Chemotherapy of Meningiomas41. Chemotherapy of Brain Metastases
SECTION V. CHEMOTHERAPY FOR SPECIFIC TUMORS - PEDIATRICS42. Chemotherapy of Pediatric Low-Grade Gliomas43. Chemotherapy of Pediatric High-Grade Gliomas44. Chemotherapy for Medulloblastoma45. Chemotherapy of Brainstem Gliomas46. Germ Cell Tumors47. Chemotherapy of Ependymoma - Childhood48. Chemotherapy for CNS Atypical Teratoid/Rhabdoid Tumor49. Chemotherapy of Central Nervous System Primitive Neuro-Ectodermal Tumors50. Pediatric Choroid Plexus Carcinoma: Current Management and Future Directions
SECTION VI. IMMUNOTHERAPY OF BRAIN TUMORS51. The Immune Response to Glioblastoma: Overview and Focus on Checkpoint Blockade52. Blockade of the Checkpoint Inhibitor Pathways and Activated T-cell Therapy in Brain Tumors53. Overview of Dendritic Cell Vaccines for Brain Tumors54. Overview of Vaccine Strategies against Epidermal Growth Factor Receptor in Brain Tumors55. Overview of CNS Vaccines - Pediatrics
SECTION VII. RESPONSE ASSESSMENT, QUALITY OF LIFE, AND NEUROPSYCHOLOGY56. Issues in Response Assessment of Brain Tumor Chemotherapy57. Pseudoprogression in Neuro-Oncology: Overview, Pathophysiology, and Interpretation58. Response assessment in neuro-oncology (RANO): An update 59. Immunotherapy Response Assessment in Neuro-Oncology (iRANO)60. Quality of Life in Neuro-Oncology61. Neuropsychology of Chemotherapy in Brain Tumor Patients
About the author
Herbert B. Newton, M.D., FAAN, is currently the Medical Director for the Neuro-Oncology Program and Brain Tumor Institute at the University Hospitals Cleveland Medical Center and Seidman Cancer Center, in Cleveland, Ohio, where he is also a Professor of Neurology and Solid Tumor Oncology, and holds the William Burton Risman Neurological Institute Chair in Memory and Cognition. Prior to that he was the Director of the Neuro-Oncology Center and Medical Neuro-Oncology Program at the Advent Health Cancer Institute and Advent Health Orlando Campus in Orlando, Florida. He is also retired as a Professor of Neurology and Neurosurgery, Dardinger Neuro-Oncology Center, Esther Dardinger Endowed Chair in Neuro-Oncology and Division of Neuro-Oncology at the Ohio State University Medical Center and James Cancer Hospital, in Columbus, Ohio. He is a Diplomate of the American Board of Psychiatry and Neurology, a Fellow of the American Academy of Neurology and Royal Society of Medicine, and a member of numerous national and international societies.
